Testing kidney nerve stimulation in people with irregular heartbeat and high blood pressure
Tests brief kidney nerve stimulation in adults with irregular heartbeat and high blood pressure.
Plain-language title generated from the registry record
Registry title: Renal Denervation in Patients With Atrial Fibrillation and Hypertension
Key facts
- Where
- London, CanadaSee the site
Where in Canada
- London Heart Rhythm ProgramLondon, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Pavel Antiperovitch
- Trial code
- NCT07893821
- Record updated
- 26 October 2026
- Original description
High blood pressure is a major risk factor for atrial fibrillation (AF), an irregular heart rhythm, and heart failure with preserved ejection fraction (HFpEF), a condition in which the heart becomes stiff and cannot relax properly. Both conditions can significantly affect quality of life and frequently occur together. In individuals with high blood pressure, increased activity of the nerves surrounding the kidneys can further elevate blood pressure and contribute to strain on the heart.Read full original descriptionShow less
A Pilot Study Evaluating Renal Denervation in Heart Failure Patients: A Two-Phase Prospective Study - Phase 1
High blood pressure is a major risk factor for atrial fibrillation (AF), an irregular heart rhythm, and heart failure with preserved ejection fraction (HFpEF), a condition in which the heart becomes stiff and cannot relax properly. Both conditions can significantly affect quality of life and frequently occur together. In individuals with high blood pressure, increased activity of the nerves surrounding the kidneys can further elevate blood pressure and contribute to strain on the heart.
Renal denervation (RDN) is a procedure designed to lower blood pressure by reducing the activity of these nerves using a thin catheter and controlled energy. RDN has been shown to lower blood pressure safely in many patients; however, the potential benefits in individuals with concurrent AF and HFpEF remain uncertain.
This pilot study will be conducted in two phases. Phase 1 will assess the safety and feasibility of accessing the renal arteries and evaluating blood pressure responses to brief electrical stimulation of the renal nerves.
Inclusion: Age ≥18 years; Scheduled for EP study +/- catheter ablation; Adequate renal function (eGFR ≥45 mL/min/1.73m²).
Exclusion: Previous renal artery intervention; Hemodynamic instability; Renal artery stenosis >50%; Single functioning kidney; Pregnancy or nursing; Life expectancy <12 months; Unwilling or unable to provide informed consent; Participation in a clinical trial that may impact the outcomes of the current study.